Abstracts tagged "giant cell arteritis"

Abstract Number: 2918 • 2019 ACR/ARP Annual Meeting
Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis
Mitsuhiro Akiyama ¹, Hui Zhang ¹, Ryu Watanabe ¹, Toshihisa Maeda ², Gerald Berry ¹, Jorg Goronzy ¹ and Cornelia Weyand¹, ¹Stanford University, Stanford, CA, ²Matsubara Mayflower Hospital, Kobe, Japan
Background/Purpose: Giant cell arteritis (GCA) is an autoimmune vasculitis that causes aortic arch syndrome, blindnesss, and stroke. Embedded in granulomatous infiltrates, CD4 T cells persist…
Abstract Number: 2650 • 2019 ACR/ARP Annual Meeting
Predictors of Relapse in Giant Cell Arteritis: Data from an International Collaboration
Laure Delaval ¹, Raphael Porcher ², Kenneth Warrington ³, Francesco Muratore ⁴, Cynthia Crowson ⁵, Daniel Blockmans ⁶, Christian Agard ⁷, Alexis Régent ⁸, Maxime Samson ⁹, Loic Guillevin ⁸, Carlo Salvarani ¹⁰ and Benjamin Terrier⁸, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²Hotel Dieu Hospital, Paris, France, ³Mayo Clinic Rochester, Rochester, MN, ⁴Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵Mayo Clinic Rochester, Rochester, ⁶Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁷CHU Nantes, Nantes, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁹Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ¹⁰Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Roughly half of giant-cell arteritis (GCA) patients taking only glucocorticoids (GCs) relapse. The relapse rate seems to reflect, in part, the duration of GC intake, more…
Abstract Number: 2675 • 2019 ACR/ARP Annual Meeting
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
Jennie Best¹, Amanda M. Kong ², Oth Tran ² and Margaret Michalska ¹, ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Cambridge, MA
Background/Purpose: Oral glucocorticoids (OGC) have been the mainstay of treatment for giant cell arteritis (GCA). However, OGCs are associated with several adverse events (AEs). The…
Abstract Number: 2920 • 2019 ACR/ARP Annual Meeting
Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, David Cuthbertson ⁴, Simon Carette ⁵, Gary S. Hoffman ⁶, Nader A. Khalidi ⁷, Curry L. Koening ⁸, Carol Langford ⁹, Kathleen Maksimowicz-McKinnon ¹⁰, Carol A. McAlear ¹¹, Paul Monach ¹², Larry Moreland ¹³, Christian Pagnoux ¹⁴, Kaitlin Quinn ¹⁵, Joanna Robson ¹⁶, Philip Seo ¹⁷, Antoine Sreih ¹⁸, Ravi Suppiah ¹⁹, Kenneth Warrington ²⁰, Steven Ytterberg ²¹, Raashid Luqmani ³, Richard Watts ²², Peter Merkel ¹⁸ and Peter C. Grayson ²³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Utah Hospital, Salt Lake City, UT, ⁹Cleveland Clinic, Cleveland, OH, ¹⁰Henry Ford Hospital, Wayne State University, Detroit, MI, ¹¹University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University of Pittsburgh, PITTSBURGH, PA, ¹⁴Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁵Georgetown University Hospital/National Institutes of Health, Washington, DC, ¹⁶Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ¹⁷Johns Hopkins Medicine, Baltimore, MD, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ²⁰Mayo Clinic Rochester, Rochester, MN, ²¹Mayo Clinic College of Medicine, Rochester, MN, ²²Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ²³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Current classification criteria differentiate between Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), the two most common forms of large-vessel vasculitis, based primarily on…
Abstract Number: 2651 • 2019 ACR/ARP Annual Meeting
Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups?
Berkan Armagan ¹, Abdullah Yildirim ², Alper Sarı ³, Bayram Farisoğulları ³, Emre Bilgin ³, Levent Kilic ⁴, Umut Kalyoncu ⁵, Şule Apras Bilgen ⁴ and Omer Karadag⁶, ¹Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ³Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ⁴Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁵Hacettepe University Department of Rheumatology, Ankara, Turkey, ⁶Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey
Background/Purpose: In parallel to the improvements in imaging, increasing data is accumulated regarding phenotypes of primary vasculitides. Giant cell arteritis (GCA) is a large vessel…
Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Aladdin Mohammad¹, Pavlos Stamatis ¹ and Aleksandra Turkiewicz ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…
Abstract Number: 2921 • 2019 ACR/ARP Annual Meeting
High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis
Christine rodriguez ¹, Wagih Ben Hassen ¹, Pierre Seners ², Catherine Oppenheim ¹ and Alexis Régent³, ¹Département d’imagerie, pôle Neuro Sainte Anne, GHT Paris – Psychiatrie & Neurosciences, 1 rue Cabanis, 75014 Paris, Paris, Ile-de-France, France, ²Service de neurologie, pôle Neuro Sainte Anne, GHT Paris – Psychiatrie & Neurosciences, 1 rue Cabanis, 75014 Paris, Paris, Ile-de-France, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis of large arteries affecting people older than 50 years. Temporal artery biopsy (TAB)…
Abstract Number: 2652 • 2019 ACR/ARP Annual Meeting
Comparison Between Transmural and Isolated Periadventitial And/or Adventitial Inflammation at Temporal Artery Biopsy: A Single Center Cohort of Biopsy-Positive GCA with Long Term Follow-up
Elena Galli¹, Francesco Muratore ², Luigi Boiardi ³, Alberto Cavazza ⁴, Giovanna Restuccia ², Luca Cimino ⁵ and Carlo Salvarani ⁶, ¹Division of Rheumatology, University of Modena and Reggio Emilia, Modena, Italy, ²Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Pathology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵Ophthalmology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁶Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). In some cases, inflammation…
Abstract Number: 2677 • 2019 ACR/ARP Annual Meeting
Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study
Aladdin Mohammad¹, Aleksandra Turkiewicz ², Pavlos Stamatis ¹, Carl Turesson ³, Martin Englund ² and Ali Kiadaliri ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malmö, Sweden
Background/Purpose: To study the healthcare resource utilization (HRU) in patients with giant cell arteritis (GCA) compared with the background population in southern Sweden.Methods: The study…
Abstract Number: 2923 • 2019 ACR/ARP Annual Meeting
Clinical Subsets in Giant Cell Arteritis
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, Joanna Robson ⁴, Ravi Suppiah ⁵, Richard Watts ⁶, Raashid Luqmani ³, Peter Merkel ⁷ and Peter C. Grayson ⁸, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁵Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Giant cell arteritis (GCA) is a clinically heterogeneous disease. Disease subsets based upon cranial versus extracranial artery involvement have been proposed. The study objective…
Abstract Number: 2747 • 2018 ACR/ARHP Annual Meeting
Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival
Stig Tengesdal and Geirmund Myklebust, Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway
Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are used as adjunct immunosuppressants and corticosteroid sparing agents in treatment of Giant Cell Arteritis (GCA), but the efficacy…
Abstract Number: 2991 • 2018 ACR/ARHP Annual Meeting
Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
Pavlos Stamatis¹, Carl Turesson², Minna Willim³, Jan-Åke Nilsson⁴, Martin Englund⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁶Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: To investigate the cancer risk in patients with biopsy-proven giant cell arteritis (GCA). Methods: The study population consisted of 830 patients (74 % women)…
Abstract Number: 2748 • 2018 ACR/ARHP Annual Meeting
Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT
Diana Prieto Peña¹, Javier Loricera², Monica Calderón Goercke¹, Francisco Javier Narváez³, Elena Aurrecoechea⁴, Ignacio Villa-Blanco⁵, Santos Castañeda⁶, Catalina Gómez-Arango⁷, Noelia Álvarez-Rivas⁸, Antonio Mera⁹, Eva Perez Pampín⁹, Vicente Aldasoro¹⁰, Nagore Fernandez-Llanio Cornella¹¹, Maria Concepcion Alvarez de Buergo¹², Luisa Marena Rojas Vargas¹³, Francisca Sivera¹⁴, Eva Galindez-Agirregoikoa¹⁵, Roser Solans¹⁶, Susana Romero-Yuste¹⁷, Belén Atienza-Mateo¹⁸, José Luis Martín-Varillas¹⁸, Isabel Martínez-Rodríguez¹⁹, Ignacio Banzo¹⁹, Vanesa Calvo-Río¹⁸, Natalia Palmou-Fontana¹⁸, José Luis Hernández², Miguel Angel González-Gay¹⁸ and Ricardo Blanco¹⁸, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ⁴Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ⁸Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ⁹Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ¹¹Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ¹²Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ¹³Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ¹⁴Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁵Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁶Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ¹⁷Hospital de Pontevedra. Spain, Pontevedra, Spain, ¹⁸Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁹Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis which can involve the aorta and/or its major branches. Tocilizumab (TCZ) seems to be effective in…
Abstract Number: 2995 • 2018 ACR/ARHP Annual Meeting
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Jennie H. Best¹, Amanda Kong², David Smith², Ibrahim Abbass¹ and Margaret Michalska¹, ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Bethesda, MD
Background/Purpose: To quantify the healthcare expenditures associated with oral glucocorticoids-related-adverse events (OGCs-AEs), among patients in the US with giant cell arteritis (GCA) using claims data…
Abstract Number: 2753 • 2018 ACR/ARHP Annual Meeting
Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis
Monica Calderón Goercke¹, Javier Loricera², Diana Prieto Peña¹, Francisco Javier Narváez³, Elena Aurrecoechea⁴, Ignacio Villa-Blanco⁵, Santos Castañeda⁶, Catalina Gómez-Arango⁷, Antonio Mera⁸, Eva Perez Pampín⁸, Vicente Aldasoro⁹, Noelia Álvarez-Rivas¹⁰, Nagore Fernandez-Llanio Cornella¹¹, Maria Concepcion Alvarez de Buergo¹², Luisa Marena Rojas Vargas¹³, Francisca Sivera¹⁴, Eva Galindez-Agirregoikoa¹⁵, Roser Solans¹⁶, Susana Romero-Yuste¹⁷, Norberto Ortego Centeno¹⁸, Marcelino Revenga Martínez¹⁹, Rafael Melero²⁰, Eva Salgado-Pérez²¹, Sabela Fernández²², José Luis Martín-Varillas²³, Isabel Martínez-Rodríguez²⁴, Ignacio Banzo²⁴, Vanesa Calvo-Río²³, Belén Atienza-Mateo²³, Natalia Palmou-Fontana²³, Carmen González-Vela²⁵, José Luis Hernández², Miguel Angel González-Gay²³ and Ricardo Blanco²³, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ⁴Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ⁸Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ⁹Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ¹⁰Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹¹Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ¹²Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ¹³Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ¹⁴Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁵Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁶Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ¹⁷Hospital de Pontevedra. Spain, Pontevedra, Spain, ¹⁸Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁹Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ²⁰Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ²¹Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ²²Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²⁴Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a predisposition for the cranial branches of the external carotid artery. However, aorta and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].